RETRACTED ARTICLE: Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer

Campos, Pedro Antonio Cascales; Francisco-Cristobal, Muñoz-Casares; González-Gil, Alida; Sánchez-García, Susana; Israel, Manzanedo; Rafael, M. Neto; Padilla-Valverde, David; Villarejo, Pedro; Fernando, Pereira; Elena, G.; J, Gil

doi:10.1007/s10585-019-10010-5

Cited by 5 publications

(4 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other studies, patients underwent HIPEC with different doses of cisplatin [14,22,23]. In the study by Antonio et al, patients were treated with HIPEC and paclitaxel alone [21]. Hence, several investigations have shown that dose dense chemotherapy provides clinical bene ts.…”

Section: Discussionmentioning

confidence: 99%

“…In some studies, HIPEC was administered only after optimal cytoreductive surgery using cisplatin or a combination of doxorubicin, paclitaxel, or mitomycin C [8,[18][19][20]. In other studies, patients received HIPEC with different doses of cisplatin [14,[21][22][23]. Numerous investigations conducted to assess dose dense chemotherapy have shown clinical bene ts.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Dense Hyperthermic Intraperitoneal Chemotherapy with Cisplatin in Patients with Stage III Serous Epithelial Ovarian Cancer: A Retrospective Study

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: To investigate the efficacy and safety of interval debulking surgery (IDS) combined with dense hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in Chinese patients with FIGO stage III serous epithelial ovarian cancer (EOC).Methods: This retrospective single-center study reviewed the demographic and clinical data of 197 patients with primary FIGO stage III serous EOC who were treated with IDS with (n=121) or without (n=76, control group) dense HIPEC between January 2012 and April 2017. The co-primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoint was the occurrence of adverse events.Results: The median PFS was 24 months in the IDS plus dense HIPEC group, whereas it was 19 months in the IDS alone group (hazard ratio [HR] 0.46, 95% confidence interval [CI]: 0.33-0.65, p=0.000). The median OS in patients treated with IDS plus dense HIPEC (51 months) was significantly longer than that in patients treated with IDS alone (40 months, HR 0.52, 95% CI: 0.35-0.78, p=0.001). The demographic and preoperative clinical characteristics of these two groups were comparable (p>0.05). In the IDS alone group, no adverse events were recorded in 42 (55.3%) of the 76 patients, and 14 (18.4%) patients were reported to have grade III/IV adverse events. In the IDS plus dense HIPEC group, no adverse events were recorded in 55 (45.5%) of the 121 patients, and 23 (19.0%) patients were reported to have grade III/IV adverse events. No postoperative deaths occurred within 30 days in either group and neither did severe fatal complications in the IDS plus dense HIPEC group.Conclusions: IDS plus dense HIPEC with cisplatin in Chinese patients with FIGO stage III serous EOC is associated with improved survival and is reasonably well tolerated by patients.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Dense Hyperthermic Intraperitoneal Chemotherapy with Cisplatin in Patients with Stage III Serous Epithelial Ovarian Cancer: A Retrospective Study

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…In some studies, HIPEC was administered only after optimal cytoreductive surgery using cisplatin or a combination of doxorubicin, paclitaxel, or mitomycin C (Cascales Campos et al, 2011;Ceresoli et al, 2018;Delotte et al, 2015;Safra et al, 2014). In other studies, patients received HIPEC with different doses of cisplatin (Antonio et al, 2019;Ba et al, 2014;Deraco et al, 2011;van Driel et al, 2018). Numerous investigations conducted to assess dose dense chemotherapy have shown clinical bene ts.…”

Section: Introductionmentioning

confidence: 99%

“…In other studies, patients underwent HIPEC with different doses of cisplatin(Ba et al, 2014;Deraco et al, 2011;van Driel et al, 2018). In the study by Antonio et al, patients were treated with HIPEC and paclitaxel alone(Antonio et al, 2019). Hence, several investigations have shown that dose dense chemotherapy provides clinical bene ts.…”

mentioning

confidence: 99%

Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study

Wei

et al. 2021

Preprint

View full text Add to dashboard Cite

Purpose: To investigate the efficacy and safety of interval debulking surgery (IDS) combined with dense hyperthermic intraperitoneal chemotherapy (HIPEC) with cisplatin in Chinese patients with FIGO stage III serous epithelial ovarian cancer (EOC).Methods: This retrospective single-center study reviewed the demographic and clinical data of 197 patients with primary FIGO stage III serous EOC who were treated with IDS with (n=121) or without (n=76, control group) dense HIPEC between January 2012 and April 2017. The co-primary endpoints were progression-free survival (PFS) and overall survival (OS), and the secondary endpoint was the occurrence of adverse events.Results: The median PFS was 24 months in the IDS plus dense HIPEC group, whereas it was 19 months in the IDS alone group (hazard ratio [HR] 0.46, 95% confidence interval [CI]: 0.33-0.65, p=0.000). The median OS in patients treated with IDS plus dense HIPEC (51 months) was significantly longer than that in patients treated with IDS alone (40 months, HR 0.52, 95% CI: 0.35-0.78, p=0.001). The demographic and preoperative clinical characteristics of these two groups were comparable (p>0.05). In the IDS alone group, no adverse events were recorded in 42 (55.3%) of the 76 patients, and 14 (18.4%) patients were reported to have grade III/IV adverse events. In the IDS plus dense HIPEC group, no adverse events were recorded in 55 (45.5%) of the 121 patients, and 23 (19.0%) patients were reported to have grade III/IV adverse events. No postoperative deaths occurred within 30 days in either group and neither did severe fatal complications in the IDS plus dense HIPEC group.Conclusion: IDS plus dense HIPEC with cisplatin in Chinese patients with FIGO stage III serous EOC is associated with improved survival and is reasonably well tolerated by patients.

show abstract

Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval—ISPSM Collaborative Study

Somashekhar

Yethadka²,

Ashwin

et al. 2023

Indian J Surg Oncol

View full text Add to dashboard Cite

RETRACTED ARTICLE: Upfront citorreduction and hyperthermic intraperitoneal chemotherapy with paclitaxel in patients with stage III-C serous epithelial ovarian cancer

Abstract: The online version of this article contains the full text of the retracted article as electronic supplementary material.

Cited by 5 publications

References 29 publications

Dense Hyperthermic Intraperitoneal Chemotherapy with Cisplatin in Patients with Stage III Serous Epithelial Ovarian Cancer: A Retrospective Study

Dense Hyperthermic Intraperitoneal Chemotherapy with Cisplatin in Patients with Stage III Serous Epithelial Ovarian Cancer: A Retrospective Study

Dense hyperthermic intraperitoneal chemotherapy with cisplatin in patients with stage III serous epithelial ovarian cancer: a retrospective study

Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval—ISPSM Collaborative Study

Contact Info

Product

Resources

About